You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Shingrix Logo

Product menu

group of patients

Recommend SHINGRIX

Recommend SHINGRIX (herpes zoster vaccine, recombinant, adjuvanted) to your patients 50 years of age and older at their next visit.1

PREV
NEXT
patient profile 1

Meet Jennifer*

She's healthy, and still at risk of shingles**

Who is Jennifer?

Married, self-employed, takes care of her children and is very active in her running club.

Lifestyle:

  • Healthy eater
  • Daily walker
  • Frequent runner

Medical History:

No current medical issues

How would shingles affect her life?

She may not be able to both manage her business and take care of her children.

Recommendation Opportunity †:

  • When doing a 'well woman' check or menopause clinic or any routine appointment.
  • When scheduling winter vaccinations.

*Not an actual patient
**The risk of shingles increases with age, with a steep increase occurring at age 50.7
† Shingrix should be used in accordance with official recommendations.

patient profile 2

Meet Karl*

Takes care of others, even though he has a higher risk of shingles.**

Who is Karl?

Friendly dog owner and beloved neighbour who enjoys playing with his dogs and helping around the neighbourhood.

Lifestyle:

  • Too busy to exercise regularly
  • Unhealthy eating habits

Medical History:

COPD

How would shingles affect his life?

He could find it difficult to do routine tasks, and an HZ episode may exacerbate his COPD symptoms.^†

If he develops shingles he may be 2.6 times more likely to be hospitalised than shingles patients without COPD (OR:2.66; 95% CI: 2.17-3.24)2

Recommendation Opportunity †:

  • When in for patient review
  • When seeking a repeat prescription
  • When scheduling winter vaccinations

*Not an actual patient
† Shingrix should be used in accordance with official recommendations.
**The risk of shingles increases with age, with a steep increase occurring at age 50.7 COPD patients have a higher risk of herpes zoster RR 1.41 (95% CI: 1.28-1.55)8
^Survey of 735 COPD patients, of whom 192 reported previous HZ . 49 (25.5%) reported increased COPD symptoms during HZ episodes.9
†In a retrospective study from Spain. Hospitalisations with a herpes zoster ICD-9 code in any diagnostic position. Participants >50 years old (N=2,289,485, including 161,317 patients with COPD) were followed up between 2009 and 2014 using population and health databases of Valencia Region. Shingles incidence rate in patients with COPD was 11 (95% CI: 10.7–11.4) cases/1000 person-years.1 Absolute rates of hospitalisation not reported in publication.

patient profile 4

Meet Susan*

As she adjusts to life as a caregiver, she needs protection from shingles.**

Who is Susan?

Married mother of two college graduates, caretaker of her ailing mother, and a non-profit organisation co-founder.

Lifestyle:

  • Eats well
  • Exercises frequently

Medical History:

Type 2 diabetes that is well controlled

How would shingles affect her life?

If Susan develops shingles, she may be 1.6x more likely to be hospitalised vs patients with shingles without diabetes (OR: 1.63; 95% CI: 1.38–1.91).10*
Shingles could disrupt the care she provides to her mother and may increase her HbA1c levels.10^

Recommendation Opportunity †:

  • When she is in for her 'Chronic Disease Management' consultation or for a routine check-up.
  • When seeking a repeat prescription
  • When in for seasonal vaccinations

*Not an actual patient
† Shingrix should be used in accordance with official recommendations.
**The risk of shingles increases with age, with a steep increase occurring at age 50.7
^Retrospective cohort of 2,289,485 subjects >50 years from Spain, 397,940 of whom had diabetes. 24% of patients with well-controlled diabetes (HbA1c ≤ 6.5%) before the shingles diagnosis had increased HbA1c levels after the shingles diagnosis (HbA1c > 6.5%).10

More information on SHINGRIX

greater than 90% Efficacy against Herpes Zoster icon

How efficacious is SHINGRIX?

SHINGRIX demonstrated >90% efficacy against shingles in adults 50 years of age and older based on pooled data from two large, phase 3 randomised controlled trials.1,3,4

*ZOE-50 median follow-up 3.1 years. ZOE-70 median follow-up 4 years.

View efficacy data

varicella zoster virus

Addressing age-related decline in immunity.

SHINGRIX – specifically formulated to help address age-related decline in varicella zoster virus specific immunity in adults 50 years of age and older.1,5,6

SCIENTIFIC RATIONALE

two syringes showing a two dose schedule

Ready to vaccinate with SHINGRIX?

Familiarise yourself with the dosing and administration of SHINGRIX.1

Dosing and administration

References

  1. Shingrix, Summary of Product Characteristics (SPC), available on https://www.medicines.ie/medicines/shingrix-powder-and-suspension-for-suspension-for-injection-herpes-zoster-vaccine-recombinant-adjuvanted--35192/spc. Last Accessed: November 2025
  2. Muñoz-Quiles C, López-Lacort M, Díez-Domingo J. Risk and impact of herpes zoster among COPD patients: a population-based study, 2009-2014. BMC Infect Dis. 2018;18:203
  3. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015 May;372 (22):2087-96.
  4. Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang S-J, Diez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016 Sep;375 (11):1019-32.
  5. Chlibek R, Smetana J, Pauksens K, Rombo L, Van den Hoek JA, Richardus JH, et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine. 2014 Mar;32 (15):1745-53.
  6. Leroux-Roels I, Leroux-Roels G, Clement F, Vandepapelière P, Vassilev V, Ledent E, Heineman TC. A phase 1 /2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis. 2012 Oct;206 (8):1280-90.
  7. Centers for Disease Control and Prevention. Shingles Vaccination. Reviewed July 19, 2024. November 2025. https://www.cdc.gov/shingles/vaccines/
  8. Marra F, Parhar K, Huang, B, et al. Risk Factors for Herpes Zoster Infection: A Meta-Analysis. Open Forum Infect Dis. 2020;7(1):ofaa005
  9. Yawn; Knowledge and Attitudes Concerning Herpes Zoster among People with COPD: An Interventional Survey StudyYP; Vaccine;2022;10;1-13
  10. Muños-Quiles C, Lópes-Lacort M, Ampudia-Blasco FJ, et al. Risk and impact of herpes zoster on patients with diabetes: a population-based study, 2009-2014. Human Vacc Immunother. 2017;13(11):2606-11. doi.org/10.1080/21645515.2017.1368600

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

SHINGRIX is owned by or licensed to the GSK group of companies. © 2025 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.

PM-IE-SGX-WCNT-210006 | Date of Preparation: November 2025